Generation of Probiotic-Based Multifunctional Hydrogels Capable of Carrying Oxygen and Anti-Inflammatory Drugs and Their Effect on Cell Viability Under Hypoxic Conditions.

Authors

Ulvi Suleymanzade, Yağmur Damla Demir, Dilek Tepeli, Tuğba Ezgi Şahin, Nermin Seda Kehr

Published in

Journal of biomedical materials research. Part A. Volume 114. Issue 10. Pages e70150.

Abstract

Hypoxia and chronic inflammation have an interdependent relationship, as they stimulate each other. Under inflammation, hypoxia occurs in tissues and under hypoxia, transcription factors induce overproduction of pro-inflammatory cytokines, causing the chronic inflammatory process. There are very few studies that combine O₂ with anti-inflammatory agents to simultaneously reduce the effects of hypoxia and inflammation. However, despite the important role of probiotic metabolites in regulating pro-inflammatory cytokines, none of these studies have addressed the combined use of O₂, anti-inflammatory agents, and probiotic metabolites to effectively inhibit the harmful effects of hypoxia and inflammation. In this context, we report a biomaterial (GA-^RutPMOF-CAP) consisting of a GelMA-Alginate (GA) hydrogel matrix incorporating rutin-loaded, perfluorocarbon-functionalized periodic mesoporous organosilica (^RutPMOF) nanoparticles and probiotic-loaded alginate microcapsules (CAP), capable of delivering sustained O₂, probiotic-derived metabolites, and pH-sensitive anti-inflammatory drug release. GA-^RutPMOF-CAP, which provides approximately 90% release of the anti-inflammatory drug (Rut) at pH 6.0, > 5% O₂ release within the first 5 days under hypoxic conditions, and release of probiotic metabolites over a 7-day incubation period. GA-^RutPMOF-CAP does not increase the production of reactive oxygen species (ROS) during 1 and 7 day incubation periods under hypoxic conditions. Furthermore, GA-^RutPMOF-CAP supports cell viability under hypoxia and promotes a decrease in TNF-α levels under LPS-stimulated normoxic conditions; this demonstrates that GA-^RutPMOF-CAP has beneficial effects on cells under inflammatory-like conditions.

PMID:
42803184
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.